MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE:MDT) today announced that reducing right ventricular pacing to less than 10 percent in patients with dual chamber pacemakers reduced the relative risk of developing persistent atrial fibrillation (AF) by 40 percent compared with conventional dual chamber pacing in a trial of more than 1,000 patients with sinus node disease. The trial, called SAVE PACe (The Search AV Extension and Managed Ventricular Pacing for Promoting Atrioventricular Conduction) was funded by Medtronic and is published in this week’s The New England Journal of Medicine.
